Search results
11 lis 2017 · Once the diagnostic evaluation is complete, treatment is guided by the AA severity, established by the Camitta criteria (Figure 1) [16, 17]. For younger patients with severe aplastic anemia (SAA) or very severe aplastic anemia (VSAA), a transplant evaluation should be rapidly initiated.
1 kwi 2019 · Although a rare disease, aplastic anemia should be distinguished from other cases of pancytopenia, and patients should receive the best treatment available based on their age, and the existence of a matched sibling donor.
28 cze 2024 · Patients treated with IST need life-long monitoring by BM biopsies with cytogenetics and NGS to allow timely intervention with allogeneic HCT for MN. Even so, allogeneic HCT for monosomy 7 AML, for example, provides a 2-year leukemia-free survival of only 28.5% and a 2-year OS of 34.9% [ 18 ].
6 sty 2022 · Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant (BMT) or immunosuppression (IST) depending on their age, comorbidities, and available donors.
5 sty 2024 · Researchers found that 5-year overall survival was: 90.5% for adults ages 19–39 years. 70.7% for adults ages 40–59 years. 38.1% for adults ages 60 years or older. A 2019 study retrospectively...
5 sty 2022 · Aplastic anemia is the prototype of the bone marrow failure syndromes that are characterized by hypocellular marrow and pancytopenia, and severe aplastic anemia is fatal if untreated. 1...
22 cze 2021 · Minor population of CD55−CD59− blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.
